logo
  

Federal Realty Q1 Results Beat Street View

Federal Realty Investment Trust (FRT) on Wednesday reported first-quarter net income of $46.2 million or $0.60 per share, down from $52.8 million or $0.70 per share in the year-ago quarter.

On average, 3 analysts polled by Thomson Reuters expected the company to report earnings of $0.19 per share in the quarter. Analysts' estimates, usually, exclude one-time items.

During the quarter, funds from operations or FFO came in at $91.1 million or $1.17 per share, lower than $114.3 million or $1.50 per share in the same period last year.

Quarterly revenues declined to $218.2 million from $231.6 million in the previous-year period while analysts were expecting revenues of $209.5 million in the period.

The company' also declared a regular quarterly cash dividend of $1.06 per share, payable on July 15 to common shareholders of record as of June 22.
Looking ahead, for full-year 2021, the company expects earnings per share between $1.54 to $1.70 while six analysts expect the company to report earnings of $1.11 per share in the year. For full year 2021, FFO per share guidance was between $4.54 and $4.70.

In 2022, Federal Realty expects earnings per share in the $1.74-$1.94 range and analysts are looking for earnings of $1.69 per share. For full year 2022, FFO per share guidance is in the $5.05-$5.25 range.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Southwest Airlines' flights across the United States were delayed for hours on Monday evening due to technical issue in a weather information system by a third-party weather data provider. The airline later resumed flight operations after solving the issue, but there were delays. The United Kingdom's Competition and Markets Authority or CMA announced Tuesday that it has launched a market study into mobile ecosystems of technology giants Apple Inc. (AAPL) and Google, Inc. (GOOG) over concerns they have market power which is harming users and other businesses. The CMA is taking... Eli Lilly and Co. (LLY) announced Tuesday that it will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Nurtec ODT (rimegepant), an orally disintegrating tablet patients take every other day. This study will help to advance the science of migraine treatment...
RELATED NEWS
Follow RTT